In February 2000, a 7-valent pneumococcal
polysaccharide-protein conjugate vaccine
was licensed for use among infants and young children. CDC's Advisory
Committee on Immunization Practices (ACIP) recommends that the vaccine be used for all children aged 2 to 23 months and for children aged 24 to 59 months who are
at increased risk for pneumococcal disease. ACIP also recommends that the vaccine be considered for all other children aged 24 to 59 months.
Pneumococcal Disease causes wide-spread illness and death throughout the
United States each year. Pneumococcal disease kills
more people in the United States every year - 40,000 or
more - than all other vaccine preventable diseases
combined. This Vidyya contains both the complete immunization recommendations and an excellent book chapter from the CDC regarding pneumococcal disease.
The National Center for Complementary and Alternative Medicine (NCCAM), a component of the National Institutes of Health (NIH) announced plans to establish two specialized centers to conduct basic and clinical research on complementary and alternative medicine (CAM) therapies for cancer.
Today's Vidyya has information about the Prostate Cancer Outcomes Study (PCOS). PCOS was initiated in 1994 by researchers at the National Cancer Institute (NCI) to look at the impact that treatments for primary prostate cancer have on the quality of life of patients. Results of the study are being widely published. Get a list of current publications and a quick background on PCOS.
Finally, in FDA news, the Pharmacia Corporation announced
today that the U.S. Food and Drug Administration (FDA) approved Lunelle ®
Monthly Contraceptive Injection (medroxyprogesterone acetate and estradiol
cypionate injectable suspension), the first and only once-a-month
contraceptive option for women in the U.S. Lunelle, a combined hormonal
injectable contraceptive method, has contraceptive benefits similar to the
pill yet offers women the convenience of once-a-month dosing.
The articles in today's Vidyya are:
As always, we hope you enjoy the issue.